Isolation, structural elucidation and in vitro hepatoprotective activity of flavonoids from Glycyrrhiza uralensis

AbstractTwo new flavonoid glycosides, 2 ′,4′-dihydroxydihydrochalcone-4-O-β-d-glucopyranoside (1) and medicarpin-3-O-β-d-apiofuranosyl (1  → 2)-β-d-glucopyranoside (2), together with 34 known flavonoids were isolated from the 75% EtOH extract of the dried roots ofGlycyrrhiza uralensis Fisch. Their structures were elucidated on the basis of spectroscopic analyses. The flavonoids were classified into ten sub-types, namely, dihydrochalcone (1), pterocarpans (2–4), flavones (5–6), flavanones (7–11), chalcones (12–15), retro-chalcones (16–18), isoflavans (19–21), isoflavones (22–28), 3-arylcoumarins (29–30), and coumestans (31–36). The isolated flavonoids were evaluated for in vitro hepatoprotective activity againstd-galactosamine-induced toxicity in human hepatoma HepG2 cells.
Source: Journal of Natural Medicines - Category: Drugs & Pharmacology Source Type: research

Related Links:

Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
AbstractPurpose of ReviewLiver transplantation (LT) has been utilized in the last two decades for the treatment of selected patients with hepatocellular carcinoma (HCC). Currently, in most jurisdictions worldwide, only tumor size and number determine transplant candidacy, which may not sufficiently predict tumor behavior. Both tumor downstaging and expanding transplant criteria play an important role in expanding access to LT for HCC patients.Recent FindingsNew downstaging protocols are emerging that incorporate response to locoregional therapies (LRT) among those that initially present beyond the accepted Milan criteria. ...
Source: Current Hepatitis Reports - Category: Infectious Diseases Source Type: research
In this study, we analyzed two datasets (GSE 94508 and GSE 97332) to examine differentially expressed circRNAs markedly related to HCC pathogenesis. Using Limma package in R and WGCNA analysis, hsa_circ_0000517 was significantly up-regulated in HCC (adjusted P
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Roche today announced that the Phase III IMbrave150 study, evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) as a treatment for people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy, met both of its co-primary endpoints demonstrating statistically significant and clinically meaningful improvements i n overall survival (OS) and progression-free survival (PFS) compared with standard-of-care sorafenib.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
Publication date: Available online 17 October 2019Source: Materials Science and Engineering: CAuthor(s): Atul Dev, Ankur Sood, Subhasree Roy Choudhury, Surajit KarmakarAbstractWe have prepared a water dispersible Nanocrystalline hierarchical structure of paclitaxel using self-assembly approach. Its unique structure provides the advantage of increased payload and higher retention of a chemotherapeutic drug inside the tumor site for a prolonged period. Micron scale structure, sustained release behaviour, multichannel fluorescence property and devoid of any vehicle molecule makes it promising in treating solid tumors through ...
Source: Materials Science and Engineering: C - Category: Materials Science Source Type: research
To investigate the von Willebrand factor to ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma (HCC) in cirrhosis.
Source: BMC Gastroenterology - Category: Gastroenterology Authors: Tags: Research article Source Type: research
AbstractOvarian cancer is one of the most lethal gynecological cancers; owning to its late detection and chemoresistance, understanding the pathogenesis of this malignant tumor is much critical. Previous studies have reported that ubiquitin-specific peptidase 39 (USP39) is generally overexpressed in a variety of cancers, including hepatocellular carcinoma, gastric cancer and so forth. Furthermore, USP39 is proved to be associated with the proliferation of malignant tumors. However, the function and mechanism of USP39 in ovarian cancer have not been elucidated. In the present study, we observed that USP39 was frequently ove...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
AbstractCabozantinib, a multi-kinase inhibitor, is approved in the United States and European Union for treatment of patients with hepatocellular carcinoma following prior sorafenib treatment. In the Phase III CELESTIAL trial, hepatocellular carcinoma patients receiving cabozantinib showed longer overall survival (OS) and progression-free survival (PFS) than those receiving placebo. The approved cabozantinib (Cabometyx®) dose is 60  mg once daily with allowable dose modifications to manage adverse events (AE). Time-to-event Cox proportional hazard exposure–response (ER) models were developed to characterize ...
Source: Journal of Pharmacokinetics and Pharmacodynamics - Category: Drugs & Pharmacology Source Type: research
rs Beatty In 2015, over 850,000 people died from chronic hepatitis and hepatocellular carcinoma (HCC) caused by hepatitis B virus (HBV). A novel hepatitis B-like virus has recently been identified in domestic cats. The pathogenic potential of domestic cat hepadnavirus (DCH), for which 6.5% to 10.8% of pet cats are viremic, is unknown. We evaluated stored formalin-fixed, paraffin-embedded biopsies of diseased and normal feline liver for the presence of DCH using PCR and in situ hybridization (ISH). DCH was detected in 43% (6/14) of chronic hepatitis cases and 28% (8/29) of HCCs, whereas cholangitis (n = 6), biliary c...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
AbstractThe multikinase inhibitor sorafenib (SOR) is used to treat patients with hepatocellular and renal carcinomas. SOR undergoes CYP-mediated biotransformation to a pharmacologically activeN-oxide metabolite (SNO) that has been shown to accumulate to varying extents in individuals. Kinase inhibitors like SOR are frequently coadministered with a range of other drugs to improve the efficacy of anticancer drug therapy and to treat comorbidities. Recent evidence has suggested that SNO is more effective than SOR as an inhibitor of CYP3A4-mediated midazolam 1 ′-hydroxylation. CYP2D6 is also reportedly inhibited by SOR. ...
Source: The AAPS Journal - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Flavonoids | Hepatocellular Carcinoma | Liver Cancer | Toxicology